Beyond the FDA approval: assessing pharmaceutical market access risk for drug development strategy.
Market Access & Reimbursement
Securing reimbursement in the U.S. healthcare system is one of the most critical hurdles for biopharmaceutical and medical device companies.
With the U.S. accounting for nearly one-third of the $1.48 trillion global healthcare market, the opportunity is massive. But it comes with ever-changing policy, payer behavior, and pricing models.
At Polygon Health Analytics, we help you cut through the noise and prepare for real-world success.
U.S. Healthcare Market: Opportunity Meets Complexity
New policy shifts like the Inflation Reduction Act (IRA) and sweeping changes to Pharmacy Benefit Managers (PBMs) are reshaping how treatments are evaluated, priced, and covered.
Whether you're preparing for launch or managing a mature product, understanding these dynamics is essential for:
- Winning payer acceptance
- Ensuring patient access
- Protecting your revenue model
Strategic Support for Biopharma & MedTech Companies
We support both emerging and established healthcare innovators in developing market access strategies that work — from early-stage planning to post-launch optimization.
Our Approach to Market Access Success
Policy & Regulatory Impact Analysis
Stay ahead of legislative shifts that impact drug pricing, value assessments, and payer negotiations.
Payer Engagement & Value Communication
Develop evidence-based value stories that resonate with commercial and public payers — from ICER reviews to real-world outcomes.
Commercial Readiness & Pricing Strategy
Align internal teams around launch pricing, value dossiers, and go-to-market planning.
Partner With Experts in U.S. Market Strategy
We don't just follow the market — we help you influence it. Let's build an access and reimbursement strategy that aligns with today's regulatory reality and tomorrow’s growth opportunities.
Our Selected Publications & Presentations
Insights and updates on market access
Understanding Health Technology Assessment (HTA): A Strategic Imperative for Innovators
If you're a scientist transitioning into the biotechnology sector or an entrepreneur developing a novel therapy for an unmet medical need, one term will...
Read more
No Perfect Timing: Embracing Uncertainty in Business and Life
"Is now the right time?" It’s a question I hear often—from aspiring entrepreneurs, working parents, and close friends. Whether it’s starting...
Read more
Is Life Science Ready for AI?
A few days ago, Dr. Geoffrey Hinton, often referred to as the “Godfather of AI,” made a chilling statement: “There is a 10-20 percent probability that...
Read more
